Navigation Links
Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
Date:5/12/2008

de(TM), a novel, synthetic, peptide-based erythropoiesis-stimulating agent (ESA), is a product candidate that has demonstrated the ability to stimulate the production of red blood cells. If proven safe and effective in clinical trials, it may offer physicians and patients an alternative therapy to recombinant erythropoietin, a hormone that stimulates red blood cell formation.

Affymax and Takeda are collaborating on the development of Hematide(TM). The product will be commercialized in the European Union by Takeda. Affymax is conducting Phase 3 clinical trials for Hematide(TM) to treat anemia in chronic renal failure indications. Takeda is also focusing on a recently initiated Phase 1 clinical trial to evaluate Hematide(TM) to treat chemotherapy-induced anemia in prostate, breast and non-small cell lung cancer patients. Hematide(TM) is a trademark of Affymax.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of Hematide(TM), the potential of Nektar's PEGylation Technology, and the overall prospects for Nektar's business. These forward-looking statements involve important risks and uncertainties, including but not limited to: (i) because Hematide(TM) is still in clinical development, the risk of failure is high and can occur at any stage due to many factors including but not limited to safety and efficacy considerations; (ii) Takeda and Affymax may fail to obtain regulatory approval for Hematide(TM) in one or more indications; (iii) if Hematide(TM) does receive regulatory approval, Nektar's actua
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset Selected to Join the NASDAQ Biotechnology Index
2. USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical
3. QLT reports initial proof of concept data for punctal plug delivery technology
4. Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Entrust Chairman, President and CEO Bill Conner to Present at 8th Annual State of Technology Luncheon
7. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
8. Guided Surgery Technology Gaining Popularity in the Dental Implant Market
9. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
10. eResearchTechnology Reports First Quarter 2008 Results
11. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 DNA vaccine pioneer ... its development of JRC-LAMP-vax, an innovative and safe potential ... IC studies began this month in Hawaii, moving the ... , The Japanese red cedar releases pollen that causes ... Mountain Cedar pollen wreaks similar havoc in Colorado, New ...
(Date:8/21/2014)... August 21, 2014 His Majesty Willem-Alexander, ... , The Court of His Majesty Willem-Alexander, King of ... the Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY ... 3. , The King will take part in the ... scheduled for 11 a.m.-12:20 p.m. and tour the plant. ...
(Date:8/21/2014)... OTC Markets Group Inc. ... company, on its approval to list on The ... the best marketplace for established U.S. and global ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We ... its growth strategy and achievement of this important ...
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... Results at 2007 AACR-NCI-EORTC International Conference, ... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... on commercializing proprietary product candidates for ... announced today it presented preclinical,results demonstrating ...
... more Kansas,State University faculty have been designated ... Subbaratnam Muthukrishnan, university distinguished professor of,biochemistry, ... pathology, have been named Fellows of the ... their scientifically or socially,distinguished efforts to advance ...
... 25 Novocell, Inc., a leading stem cell,engineering ... M.D., Senior Vice President, Clinical & Regulatory Affairs ... Dr. Kolterman joined Amylin in 1992 and ... February 1997 until present and as Senior,Vice President, ...
Cached Biology Technology:ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests 2ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests 3ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests 4ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests 5K-State's Subbaratnam Muthukrishnan and Barbara Valent Named Fellows of the American Association for the Advancement of Science 2Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors 2
(Date:8/22/2014)... suffered an injury can probably remember the after-effects, including ... body is fighting back against the injury. When tissue ... to aid in tissue regeneration. An inflammatory response acts ... helping the body to heal after injuries such as ... with healing in situations in which foreign material is ...
(Date:8/22/2014)... news release is available in German . ... helper substances, in PCFs proteins are fixated in a ... stable crystals. Next, the HZB and Fudan University researchers ... used as functional materials. Their findings are being published ... (DOI: 10.1038/ncomms5634). , Proteins are sensitive molecules. Everyone knows ...
(Date:8/22/2014)... are strong antioxidants and can reduce free ... neurons against oxidative stress? Jianbo Zhao and ... Liaoning Medical University, China discovered that green ... inhibit neuronal apoptosis, indicating green tea polyphenols ... neurons under oxidative stress. The relevant study ...
Breaking Biology News(10 mins):Tissue regeneration using anti-inflammatory nanomolecules 2Proteins: New class of materials discovered 2
... Yan Liu imagine and assemble intricate structures on a ... DNA molecule, a versatile building material offering near limitless ... issue of Science , Yan and Liu, researchers ... of Chemistry and Biochemistry, reveal for the first time ...
... from grape seeds forces laboratory leukemia cells to commit ... Kentucky. They found that within 24 hours, 76 percent ... the extract. The investigators, who report their findings ... Cancer Research , a journal of the American Association ...
... be one step closer to better drought-tolerant soybean varieties. ... of all proteins and metabolites in soybeans. Once compiled, ... proteins and metabolites in soybeans grown under drought and ... recently released soybean genome, scientists will have a very ...
Cached Biology News:The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 2The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 3Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds 2Soybean database will help breeders engineer better-performing plants 2
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
... imaging controller is a successor of the ... users to comfortably observe, record and utilize ... an 8.4 inch LCD (XGA) monitor and ... cameras including the DS-Fi1 , DS-5Mc , ...
Biology Products: